The abstract is read at the publisher; the summary is JClub's.
Risk-adapted de-escalation of neoadjuvant therapy in stage II–III HER2-positive early-stage breast cancer is supported by trials showing carboplatin omission is feasible for most patients.
- Why it matters: As neoadjuvant options have expanded, clinicians need evidence-based ways to reduce toxicity without sacrificing key response outcomes, especially for patients at different risk levels.
- What they did: The review synthesizes randomized and emerging evidence spanning de-escalation from docetaxel or paclitaxel plus trastuzumab and pertuzumab, including carboplatin omission, and discusses biomarker-guided and chemotherapy-free strategies.
- The result: It proposes a risk-adapted optimization framework emphasizing circulating tumor DNA monitoring and functional imaging as response-adapted tools, alongside new high-risk options using fam-trastuzumab deruxtecan-nxki.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.